2024
Exploring Predictors of Ketamine Response in Adolescent Treatment-Resistant Depression
Lineham A, Avila-Quintero V, Bloch M, Dwyer J. Exploring Predictors of Ketamine Response in Adolescent Treatment-Resistant Depression. Journal Of Child And Adolescent Psychopharmacology 2024, 34: 73-79. PMID: 38170185, PMCID: PMC11262580, DOI: 10.1089/cap.2023.0047.Peer-Reviewed Original ResearchDepression symptom improvementTreatment-resistant depressionChildren's Depression Rating ScaleReuptake inhibitor medicationsDepression Rating ScaleSymptom improvementAntidepressant responseInhibitor medicationKetamine responseAdolescent treatment-resistant depressionRapid-acting antidepressant agentsSelective serotonin reuptake inhibitor medicationsSerotonin reuptake inhibitor medicationsKetamine’s antidepressant responseCurrent depressive episodeSevere depressive symptomsGreater symptom improvementAttention-deficit/hyperactivity disorder diagnosisFuture therapeutic useAntidepressant medicationMedication trialsCrossover trialAntidepressant agentsClinical variablesDepressive episode
2023
The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression
Lineham A, Avila-Quintero V, Bloch M, Dwyer J. The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression. Journal Of Child And Adolescent Psychopharmacology 2023, 33: 20-26. PMID: 36799961, DOI: 10.1089/cap.2022.0086.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionDepression symptom improvementAcute dissociative symptomsAntidepressant responseSymptom improvementRapid-acting antidepressant agentsSignificant associationDissociative symptomsLikelihood of responseDissociation symptomsMagnitude of associationDissociative effectsKetamine groupPediatric patientsCrossover trialPediatric populationAntidepressant agentsKetamine responseAdolescent patientsAdult studiesDepression responseSecondary data analysisTreatment responseDepressive symptomsTrial design
2022
Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial
Dwyer J, Landeros-Weisenberger A, Johnson J, Londono Tobon A, Flores J, Nasir M, Couloures K, Sanacora G, Bloch M. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. FOCUS The Journal Of Lifelong Learning In Psychiatry 2022, 20: 241-251. PMID: 37153136, PMCID: PMC10153503, DOI: 10.1176/appi.focus.22020004.Peer-Reviewed Original ResearchTreatment-resistant depressionDepression Rating ScaleIntravenous ketamineClinical trialsAdolescent treatment-resistant depressionAdult treatment-resistant depressionPlacebo-controlled clinical trialSignificant short-term efficacySerious adverse eventsPrimary outcome measureSingle intravenous infusionChildren's Depression Rating ScaleCrossover clinical trialShort-term efficacyMajor depressive disorderSingle ketamine infusionSymptoms 24 hoursLater time pointsKetamine’s safetyAdverse eventsAntidepressant medicationKetamine infusionPediatric populationSignificant morbidityIntravenous infusion
2021
Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial
Dwyer JB, Landeros-Weisenberger A, Johnson JA, Londono Tobon A, Flores JM, Nasir M, Couloures K, Sanacora G, Bloch MH. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. American Journal Of Psychiatry 2021, 178: 352-362. PMID: 33653121, DOI: 10.1176/appi.ajp.2020.20010018.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionDepression Rating ScaleIntravenous ketamineClinical trialsAdolescent treatment-resistant depressionAdult treatment-resistant depressionPlacebo-controlled clinical trialSignificant short-term efficacySerious adverse eventsPrimary outcome measureSingle intravenous infusionChildren's Depression Rating ScaleCrossover clinical trialShort-term efficacyMajor depressive disorderSingle ketamine infusionSymptoms 24 hoursLater time pointsKetamine’s safetyAdverse eventsAntidepressant medicationKetamine infusionPediatric populationSignificant morbidityIntravenous infusion
2020
Glutamate Systems in DSM-5 Anxiety Disorders: Their Role and a Review of Glutamate and GABA Psychopharmacology
Nasir M, Trujillo D, Levine J, Dwyer JB, Rupp ZW, Bloch MH. Glutamate Systems in DSM-5 Anxiety Disorders: Their Role and a Review of Glutamate and GABA Psychopharmacology. Frontiers In Psychiatry 2020, 11: 548505. PMID: 33329087, PMCID: PMC7710541, DOI: 10.3389/fpsyt.2020.548505.Peer-Reviewed Original ResearchGlutamate systemDSM-5 anxiety disordersAnxiety disordersEvidence-based pharmacological treatmentNovel pharmacological agentsSpecific glutamate receptorsPotential alternative treatmentReuptake inhibitorsPharmacological treatmentGABAergic systemGlutamate neurotransmissionClinical trialsGlutamate receptorsAnxiety disorder treatmentPharmacological agentsAlternative treatmentDisorder treatmentDisordersAnxiety symptomsPotential targetPotential roleMedicationsSignificant proportionTreatmentGlutamateHormonal Treatments for Major Depressive Disorder: State of the Art
Dwyer JB, Aftab A, Radhakrishnan R, Widge A, Rodriguez CI, Carpenter LL, Nemeroff CB, McDonald WM, Kalin NH. Hormonal Treatments for Major Depressive Disorder: State of the Art. American Journal Of Psychiatry 2020, 177: 686-705. PMID: 32456504, PMCID: PMC7841732, DOI: 10.1176/appi.ajp.2020.19080848.Peer-Reviewed Original ResearchConceptsHypothalamic pituitary thyroidMajor depressive disorderMajor depressionDepressive disorderEffective treatmentGlucocorticoid receptor antagonist mifepristoneCorticotropin-releasing factor antagonistProgesterone derivative allopregnanoloneEstrogen replacement therapyTreatment of depressionNovel effective treatmentsCommon psychiatric disordersMore effective treatmentsNumber of hormonesWorld Health OrganizationTraditional antidepressantsAdjunctive treatmentAntagonist mifepristoneCNS effectsReplacement therapyDisease burdenGonadal axesPreclinical studiesFactor antagonistsHormonal treatmentAnnual Research Review: Defining and treating pediatric treatment‐resistant depression
Dwyer JB, Stringaris A, Brent DA, Bloch MH. Annual Research Review: Defining and treating pediatric treatment‐resistant depression. Journal Of Child Psychology And Psychiatry 2020, 61: 312-332. PMID: 32020643, PMCID: PMC8314167, DOI: 10.1111/jcpp.13202.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionMajor depressive disorderAdolescent treatment-resistant depressionRisk factorsAdolescent major depressive disorderPsychotherapy treatment trialSecond-line treatmentSignificant risk factorsPediatric clinical trialsSecond leading causeSignificant health problemEvidence-based psychotherapiesCent of adolescentsMedication switchAdequate medicationSubstantial morbiditySymptom improvementInterventional treatmentMedication augmentationTreatment trialsCare treatmentClinical trialsDepressive disorderDiagnostic difficultiesLeading cause
2019
Prenatal nicotine sex-dependently alters adolescent dopamine system development
Dwyer JB, Cardenas A, Franke RM, Chen Y, Bai Y, Belluzzi JD, Lotfipour S, Leslie FM. Prenatal nicotine sex-dependently alters adolescent dopamine system development. Translational Psychiatry 2019, 9: 304. PMID: 31740669, PMCID: PMC6861272, DOI: 10.1038/s41398-019-0640-1.Peer-Reviewed Original ResearchConceptsDopamine systemStriatal dopamine transporter bindingNorepinephrine transporterCocaine-induced locomotor activityGestational day 4Role of D2Postnatal day 32Dopamine transporter bindingCatechol-O-methyl transferaseElectronic nicotine delivery systemsCocaine-induced behaviorsPublic health initiativesSex-independent effectsNicotine delivery systemsG protein couplingNaïve damsMaternal smokingNicotine patchClinical deficitsDopamine turnoverOsmotic minipumpsPlasma levelsNeurobehavioral deficitsPregnant damsReceptor expressionAntidepressants for Pediatric Patients.
Dwyer JB, Bloch MH. Antidepressants for Pediatric Patients. Current Psychiatry 2019, 18: 26-42f. PMID: 31511767, PMCID: PMC6738970.Peer-Reviewed Original Research
2018
A Developmental Perspective of Dopaminergic Dysfunction in Tourette Syndrome
Dwyer JB. A Developmental Perspective of Dopaminergic Dysfunction in Tourette Syndrome. Biological Psychiatry 2018, 84: e33-e35. PMID: 30115244, DOI: 10.1016/j.biopsych.2018.07.008.Peer-Reviewed Original Research
2017
An Integrated Neuroscience Perspective on Formulation and Treatment Planning for Posttraumatic Stress Disorder: An Educational Review
Ross DA, Arbuckle MR, Travis MJ, Dwyer JB, van Schalkwyk GI, Ressler KJ. An Integrated Neuroscience Perspective on Formulation and Treatment Planning for Posttraumatic Stress Disorder: An Educational Review. JAMA Psychiatry 2017, 74: 407-415. PMID: 28273291, PMCID: PMC5504531, DOI: 10.1001/jamapsychiatry.2016.3325.Peer-Reviewed Original ResearchMeSH KeywordsAfghan Campaign 2001-AnimalsBrainCombat DisordersConditioning, ClassicalDisease Models, AnimalEpigenesis, GeneticFearHumansHypothalamo-Hypophyseal SystemIraq War, 2003-2011Memory ConsolidationMilitary PersonnelNerve NetNeurosciencesPatient Care PlanningPituitary-Adrenal SystemStress Disorders, Post-TraumaticConceptsPosttraumatic stress disorderNeuroscience perspectiveMemory reconsolidationStress disorderCase formulationTreatment of PTSDNeuroscience-informed approachBasic learning theoryAberrant network connectivityModern neuroscience perspectiveFear conditioningRange of behaviorsTraumatic eventsPrefrontal cortexIndividual's abilityLearning theoryReconsolidationSpecific experiencesNeuroscienceCommon psychiatric illnessLimbic structuresSocial perspectiveConditioningNetwork connectivityLong-term effectsThe Nature of Nurture: How Developmental Experiences Program Adult Stress Circuitry
Dwyer JB, Ross DA. The Nature of Nurture: How Developmental Experiences Program Adult Stress Circuitry. Biological Psychiatry 2017, 81: e57-e59. PMID: 28317550, PMCID: PMC5712909, DOI: 10.1016/j.biopsych.2017.02.004.Peer-Reviewed Original ResearchKetamine as a Treatment for Adolescent Depression: A Case Report
Dwyer JB, Beyer C, Wilkinson ST, Ostroff RB, Qayyum Z, Bloch MH. Ketamine as a Treatment for Adolescent Depression: A Case Report. Journal Of The American Academy Of Child & Adolescent Psychiatry 2017, 56: 352-354. PMID: 28335880, DOI: 10.1016/j.jaac.2017.01.006.Peer-Reviewed Case Reports and Technical Notes
2016
Modern Microglia: Novel Targets in Psychiatric Neuroscience
Dwyer JB, Ross DA. Modern Microglia: Novel Targets in Psychiatric Neuroscience. Biological Psychiatry 2016, 80: e47-e49. PMID: 27601341, PMCID: PMC5371712, DOI: 10.1016/j.biopsych.2016.08.006.Peer-Reviewed Original ResearchAdolescent Maturation of Dopamine D1 and D2 Receptor Function and Interactions in Rodents
Dwyer JB, Leslie FM. Adolescent Maturation of Dopamine D1 and D2 Receptor Function and Interactions in Rodents. PLOS ONE 2016, 11: e0146966. PMID: 26784516, PMCID: PMC4718668, DOI: 10.1371/journal.pone.0146966.Peer-Reviewed Original ResearchConceptsD1/D2 interactionsImmediate early genesIEG expressionD2 receptor functionCommon neurobiological substrateMesocorticolimbic dopamine systemDopamine receptor bindingStress-related circuitryIllicit drug useFunctional neural circuitryAge-dependent changesDrugs of abuseD2 agonistDopamine D1Bed nucleusStria terminalisAdult ratsPharmacological actionsDopamine systemDrug useLow dosesBNST functionDirect D1Neuropsychiatric disordersReceptor function
2011
Modulation of cell adhesion systems by prenatal nicotine exposure in limbic brain regions of adolescent female rats
Cao J, Dwyer JB, Mangold JE, Wang J, Wei J, Leslie FM, Li MD. Modulation of cell adhesion systems by prenatal nicotine exposure in limbic brain regions of adolescent female rats. The International Journal Of Neuropsychopharmacology 2011, 14: 157-174. PMID: 20196919, PMCID: PMC5575906, DOI: 10.1017/s1461145710000179.Peer-Reviewed Original ResearchConceptsGestational nicotine treatmentLimbic brain regionsCell adhesion moleculePsychiatric disordersBrain regionsPregnant Sprague-Dawley ratsGestational day 4Prenatal nicotine exposureNicotine replacement therapyPostnatal day 35Sprague-Dawley ratsMajor psychoactive componentAdolescent female ratsCentral nervous systemQuantitative RT-PCR techniqueRT-PCR techniqueMaternal smokingNicotine treatmentNicotine exposureReplacement therapyCaudate putamenFemale ratsPrenatal treatmentNeurotransmitter systemsNeurobehavioural deficits
2010
Gestational nicotine treatment modulates cell death/survival-related pathways in the brains of adolescent female rats – ERRATUM
Wei J, Wang J, Dwyer J, Mangold J, Cao J, Leslie F, Li M. Gestational nicotine treatment modulates cell death/survival-related pathways in the brains of adolescent female rats – ERRATUM. The International Journal Of Neuropsychopharmacology 2010, 14: 285-287. DOI: 10.1017/s1461145710001100.Peer-Reviewed Original ResearchAdolescent Maturation of D1 and D2 Dopamine Receptor Interactions
Dwyer J, Martinez L, Ganddini G, Perez M, Leslie F. Adolescent Maturation of D1 and D2 Dopamine Receptor Interactions. The FASEB Journal 2010, 24: 766.1-766.1. DOI: 10.1096/fasebj.24.1_supplement.766.1.Peer-Reviewed Original ResearchD1/D2 interactionsDopamine receptor interactionsMesocorticolimbic dopamine systemImmediate early gene expressionDopaminergic drugsReceptor changesD2 agonistDirect agonistsIndirect agonistsAdult ratsLimbic systemDopamine systemDirect D1Neuropsychiatric disordersEarly gene expressionFunctional connectivityNeural circuitryDA systemBehavioral responsesAgonistsC-fosAge differencesPhRMA FoundationAdolescent maturationReceptor interaction
2009
Mechanisms underlying age differences in dopaminergic drug sensitivity
Dwyer J, Buntrock L, Khalaj A, Martinez L, Leslie F. Mechanisms underlying age differences in dopaminergic drug sensitivity. The FASEB Journal 2009, 23: 745.3-745.3. DOI: 10.1096/fasebj.23.1_supplement.745.3.Peer-Reviewed Original ResearchNeural stress systemsCritical developmental periodAge differencesNeural circuitryAdolescenceDevelopmental periodBehavioral differencesBehavioral responsesStress systemDrug abuseIndirect dopamineStereotypic behaviorAdolescentsNeuropsychiatric disordersD2-like agonist quinpiroleImportant implicationsAdult male ratsImmediate early gene expressionAgonist quinpiroleReceptor changesAdulthoodMale ratsAbuseEarly gene expressionQuinpiroleThe dynamic effects of nicotine on the developing brain
Dwyer JB, McQuown SC, Leslie FM. The dynamic effects of nicotine on the developing brain. Pharmacology & Therapeutics 2009, 122: 125-139. PMID: 19268688, PMCID: PMC2746456, DOI: 10.1016/j.pharmthera.2009.02.003.Peer-Reviewed Original ResearchConceptsNicotine exposureDevelopmental influencesAdolescent periodBrain maturationExogenous nicotineHuman brainUnique effectsMaturational periodNeural structuresLimbic systemClinical literatureNicotine replacement therapyEnvironmental stimuliEarly postnatal periodPreclinical animal modelsDevelopmental windowNicotinic acetylcholine receptorsPrenatal periodReplacement therapyEarly postnatalPostnatal periodTobacco smokeAnimal modelsAcetylcholine receptorsNicotine